Citations

Clear

4847 citation(s) found for "Yu, Eric".

Abstract P2-09-01: Population-based risk estimates of clinical subtypes of breast cancer among carriers of germline pathogenic variants in cancer predisposition genes
Yadav, Siddhartha , Huang, Hongyan , Yao, Song, Vachon, Celine M. , Martínez, Elena, Lindströem, Sara, Haiman, Christopher A. , Gaudet, Mia M. , Auer, Paul, Goldgar, David E. , Nathanson, Katherine L. , Yadav, Siddhartha , Nathanson, Katherine L , Hu, Chunling , Boddicker, Nicholas , Polley, Eric C. , Hart, Steven N. , Gnanaolivu, Rohan , Na, Jie , Yao, Song , Vachon, Celine M. , Teras, Lauren R. , Taylor, Jack A. , Sandler, Dale P. , Palmer, Julie R. , Olson, Janet E. , Neuhausen, Susan L. , Marchand, Loı̈c Le , Kooperberg, Charles , Lacey, James V. , Bertrand, Kimberly A. , Bernstein, Leslie , Ambrosone, Christine B. , Weitzel, Jeffrey N. , Kraft, Peter , Domchek, Susan M. , Couch, Fergus J.

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: P2-09-01-P2-09-01

10.1158/1538-7445.sabcs21-p2-09-01 Get It

Abstract Introduction: The risk of specific clinical subtype of breast cancer (defined by ER and HER2 status) among women in the general population who are carriers of germline pathogenic variants (PVs) in cancer predisposition genes is not well-defined. Methods: A total of 13,153 women with breast cancer (ER+/HER2-: 9381; ER+/HER2+: 1462; ER-/HER2+: 690; and ER-/HER2-: 1620) and 25,005 unaffected women (controls) from nine studies within the CAnceR RIsk Estimates Related to Susceptibility (CARRIERS) consortium that were not enriched for family history or early onset disease were included in the present analysis. A multiplex amplicon-based panel was used to perform germline sequencing for cancer predisposition genes. Case-control associations for each of the four clinical subtype of breast cancer was performed for PVs in 5 common breast cancer predisposition genes (ATM, BRCA1, BRCA2, CHEK2 and PALB2) utilizing a logistic regression model adjusting for study, age at diagnosis, race/ethnicity and family history of breast cancer. Results: The frequency of PVs in 5 genes was 3.8% for ER+/HER2-, 6.2% for ER+/HER2+, 4.2% for ER-/HER2+ and 9.3% for ER-/HER2- subtypes. PVs in BRCA1 and BRCA2 were associated with high risk (Odds Ratio (OR) >4) for all clinical subtypes of breast cancer, but the risk was highest (OR>8) for ER-/HER2- breast cancer. PVs in PALB2 were associated with high risk (OR>4) of ER-/HER2- and ER+/HER2+ subtypes and moderate risk (OR: 2-4) of ER+/HER2- breast cancer. Irrespective of the HER2 status, PVs in ATM were associated with a moderately increased risk (OR: 2-4) of ER+ breast cancer but the risk of ER- breast cancer was not elevated. In contrast, PVs in CHEK2 were associated with high risk (OR>4) of ER+/HER2+ breast cancer and moderate risk (OR: 2-4) of ER+/HER2- and ER-/HER2+ breast cancer, but the risk of ER-/HER2- breast cancer was not elevated. Conclusions: This study provides population-based estimates of risk of specific clinical subtypes of breast cancer which will be useful for genetic counseling and targeting appropriate screening strategies in PV carriers based on subtype specific risks of breast cancer. Citation Format: Siddhartha Yadav, Chunling Hu, Nicholas J. Boddicker, Eric Polley, Steven Hart, Rohan Gnanaolivu, Jie Na, Hongyan Huang, Song Yao, Celine M. Vachon, Lauren Teras, Jack A. Taylor, Dale P. Sandler, Julie R. Palmer, Janet E. Olson, Susan Neuhausen, Elena Martinez, Sara Lindstroem, Loic Le Marchand, Charles Kooperberg, Christopher Haiman, Mia M. Gaudet, James V. Lacey, Kimberly A. Bertrand, Leslie Bernstein, Paul W. Auer, Christine Ambrosone, Jeffrey N. Weitzel, Peter Kraft, David E. Goldgar, Katherine L. Nathanson, Susan M. Domchek, Fergus J. Couch, CARRIERS Consortium. Population-based risk estimates of clinical subtypes of breast cancer among carriers of germline pathogenic variants in cancer predisposition genes [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-09-01.
Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial
Frantal, Sophie, Burstein, H.J., Greil, Richard , Winer, Eric, Singer, Christian, Miller, Kathy L. , Naughton, Michelle J. , Bliss, Judith M. , Steger, Guenther G. , Nowecki, Zbigniew , Hahn, Olwen, Rugo, Hope, Pfeiler, Georg , Fohler, Hannes, Schurmans, Céline , Theall, K. P., Lu, Dongrui R. , Tenner, Kathleen , Fesl, Christian , authorship, *shared last, Bliss, Judith , Gnant, Michael , Dueck, Amylou C. , Martín, Miguel , Fox, Peter , Wolff, Antonio C. , Chan, Arlene , Colleoni, Marco , Rubovsky, Gabor , Mayer, Ingrid A. , Wolmark, Norman , Metzger, Otto , DeMichele, Angela , Mayer, Erica L. , authorship, *shared last

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: GS1-07-GS1-07

10.1158/1538-7445.sabcs21-gs1-07 Get It

Abstract Background Advances in the multidisciplinary care of hormone-receptor positive (HR+) early breast cancer (eBC) have markedly improved clinical outcomes: however, disease recurrence may still occur, particularly in patients (pts) with moderate or high-risk cancers at the time of diagnosis. The use of CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) is a standard of care for advanced breast cancer, supporting the rationale to study CDK4/6i in the eBC setting. Here we present the final protocol-planned analyses of the global phase III PALLAS trial investigating whether the addition of the CDK4/6i palbociclib (P) to adjuvant ET improves outcomes over ET alone for HR+/HER2- eBC. Methods PALLAS (PALbociclib CoLlaborative Adjuvant Study, NCT02513394) is a randomized phase III open-label trial in which pts with stage II-III HR+/HER2- eBC were randomized to receive either 2 years of P with adjuvant ET (P+ET) or ET alone. The primary endpoint is invasive disease-free survival (iDFS); secondary endpoints include distant recurrence-free survival (DRFS), locoregional recurrence-free survival (LRRFS), overall survival (OS), and safety. Mandatory biospecimen collection has supported the creation of an expansive translational science program, and long-term follow-up is planned. Revised sample size calculations required recruitment of 5600 pts in order to detect a 25% iDFS improvement in patients receiving P+ET with 85% power; this final protocol-planned analysis was planned after 469 iDFS events. Results From September 1, 2015 to November 30, 2018, 5,761 pts (median age 52 years, range 22-90) were randomized in 406 centers in 21 countries worldwide. 1,014 (17.6%) had stage IIA disease (capped) and 4,728 (82.1%) stages IIB/III. 4,754 (82.5%) had received prior (neo)adjuvant chemotherapy. After a protocol-planned 2nd interim analysis in May 2020 crossed the futility threshold, 349 P+ET pts still on active treatment stopped P and were transferred to follow-up. At the time of final analysis cutoff date (November 20, 2020), after a median follow-up of 31 months and 516 events recorded, iDFS was similar between the two arms, with 3-year iDFS of 89.3% (95% CI: 87.8-90.6%) for Palbo+ET, and 89.4% (88.0-90.7%) for ET alone (hazard ratio 0.96, 95% CI: 0.81-1.14). There was no statistically significant difference in secondary outcome endpoints. Subgroup analyses revealed no significant interactions between treatment effect and other factors (including risk category). The safety profile of P was as expected, with grade 3 or 4 neutropenia the most common side effect (safety population: 1759/2841 [61.9%] vs 11/2902 [0.4%]). Overall 42% of pts. discontinued P prior to the planned 2-year duration, 28.2% of Palbo+ET pts discontinued therapy due to adverse events, without an observed impact on survival outcomes. Conclusions Now with the full number of events, this analysis of the PALLAS trial shows that the addition of 2 years of P to ongoing adjuvant ET did not improve survival endpoints for pts with stage II-III HR+/HER2- eBC. Whether P is beneficial in the adjuvant setting for certain sub-groups of pts will be further evaluated with longer-term follow-up and by the ongoing translational science program. Support: ABCSG; AFT; Pfizer; ClinicalTrials.gov Identifier: NCT02513394; https://www.abcsg.org; https://acknowledgments.alliancefound.org Citation Format: Michael Gnant, Amylou C Dueck, Sophie Frantal, Miguel Martin, Hal Burstein, Richard Greil, Peter Fox, Antonio C Wolff, Arlene Chan, Eric Winer, Christian Singer, Kathy Miller, Marco Colleoni, Michelle Naughton, Gabor Rubovszky, Judith Bliss, Ingrid A Mayer, Guenther G Steger, Zbigniew Nowecki, Olwen Hahn, Norman Wolmark, Hope Rugo, Georg Pfeiler, Hannes Fohler, Otto Metzger, Céline Schurmans, Kathy P Theall, Dongrui R Lu, Kathleen Tenner, Christian Fesl, Angela DeMichele*, Erica L Mayer, *shared last authorship. Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr GS1-07.
Development and Validation of Instrument for Operative Competency Assessment in Selective Neck Dissection
Dowling, Eric M. , Larson, David, Carlson, Matthew L. , Dowling, Eric , Price, Daniel L.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | March 7, 2022 | Volume: 132 | Issue: 2 | Pages: 173-181

10.1177/00034894221081101 | PMID 35249359 Get It

Background: Instruments to assess surgical skills have been validated for several key indicator procedures in otolaryngology. Selective neck dissection is a core procedure for which trainees must integrate knowledge of complex head and neck anatomy with technical surgical skills. An instrument for assessment of surgical performance in selective neck dissection has not been previously developed. The objective of the current study is to develop and validate an instrument for assessing surgical competency for level II-IV selective neck dissection. Design: A Delphi working group comprised of 23 fellowship trained head and neck surgeons from 17 institutions was assembled. The modified Delphi method encompassed a 3-step process, including 2 anonymous voting rounds to successively refine individual items and establish levels of consensus. Thresholds for achieving strong consensus, at >80% agreement, were determined a priori. The resulting instrument was subsequently validated in a prospective cohort of 17 resident surgeons, spanning postgraduate year 1 to 5 training experience. Participants were asked to perform a level II-IV selective neck dissection on fresh-frozen cadaveric specimens. Performance was scored by 2 independent, blinded observers using the devised instrument and construct validity was assessed. Results: Through the modified Delphi process a final list of 30 items, considered to be the most essential items for achieving the goals of a level II-IV selective neck dissection, was developed. Construct validity was supported by a positive association between instrument scores compared to both resident postgraduate year level and number of head and neck rotations completed. Conclusion: The development and validation of a novel instrument for assessment of surgical competency in level II-IV selective neck dissection, a key indicator case in otolaryngology, is described. This new instrument may be used to provide objective feedback on overall and task-specific competency to identify surgical deficiencies and offer granular feedback to enhance surgical training.
National Network of Depression Centers' Recommendations on Harmonizing Clinical Documentation of Electroconvulsive Therapy
Zandi, Peter P. , Morreale, Michael , Reti, Irving M. , Maixner, Daniel F. , McDonald, William M. , Patel, Paresh D. , Achtyes, Eric D. , Bhati, Mahendra T. , Carr, Brent R. , Conroy, Susan K. , Cristancho, Mario A. , Dubin, Marc J. , Francis, Andrew , Glazer, Kara, Ingram, Wendy Marie , Khurshid, Khurshid, McClintock, Shawn M. , Reeves, Kevin , Rodriguez, Nelson F., Sampson, Shirlene , Seiner, Stephen J., Smetana, Roy W., Soda, Takahiro , Trapp, Nicholas T. , Wright, Jesse H. , Husain, Mustafa M. , Weiner, Richard D. , Pinjari, Omar F. , Selek, Salih , Sheline, Yvette I. , Smetana, Roy W.

Mayo Clinic

The Journal of ECT | March 4, 2022 | Volume: 38 | Issue: 3 | Pages: 159-164

10.1097/yct.0000000000000840 | PMID 35704844 Get It

Abstract Electroconvulsive therapy (ECT) is a highly therapeutic and cost-effective treatment for severe and/or treatment-resistant major depression. However, because of the varied clinical practices, there is a great deal of heterogeneity in how ECT is delivered and documented. This represents both an opportunity to study how differences in implementation influence clinical outcomes and a challenge for carrying out coordinated quality improvement and research efforts across multiple ECT centers. The National Network of Depression Centers, a consortium of 26+ US academic medical centers of excellence providing care for patients with mood disorders, formed a task group with the goals of promoting best clinical practices for the delivery of ECT and to facilitate large-scale, multisite quality improvement and research to advance more effective and safe use of this treatment modality. The National Network of Depression Centers Task Group on ECT set out to define best practices for harmonizing the clinical documentation of ECT across treatment centers to promote clinical interoperability and facilitate a nationwide collaboration that would enable multisite quality improvement and longitudinal research in real-world settings. This article reports on the work of this effort. It focuses on the use of ECT for major depressive disorder, which accounts for the majority of ECT referrals in most countries. However, most of the recommendations on clinical documentation proposed herein will be applicable to the use of ECT for any of its indications.
Sinonasal Mucosal Melanoma: An Analysis of Treatment-Related Complications and Associated Factors
Johnson, Brian J. , Guo, Ray, Moore, Eric J. , Link, Michael J. , Peris‐Celda, Maria , Stokken, Janalee K., Guo, Ray, Price, Daniel L. , Abel, Kathryn M. Van , Gompel, Jamie J. Van , Pinheiro‐Neto, Carlos , Choby, Garret

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 4, 2022 | Volume: 83 | Issue: S 01 | Pages: S1-S270

10.1055/s-0042-1743809 Get It

Retrospective Review of Surgical Site Infections after Endoscopic Endonasal Approaches for Parasellar Masses: A Multicenter Study from the North American Skull Base Society
Saleh, Sara , Sullivan, Stephen E., Glancz, Laurence , Zwagerman, Nathan T. , Adappa, Nithin D. , Rassekh, Chris, Gardner, Paul A. , Field, Melvin , Rangarajan, Sanjeet V., Jang, David W. , Roxbury, Christopher R. , Wilson, Meghan, Patel, Shivan, Evans, Jim, Nyquist, Gurston , Khalafallah, Adham M. , Mukherjee, Raj, Adappa, Nithin D. , Snyderman, Carl H , Wang, Eric W , Choby, Garret , Gompel, Jamie J. Van , Goyal, Neerav , Zacharia, Brad E. , Çeltikçi, Emrah , D’Souza, Glen , McKean, Erin L.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 4, 2022 | Volume: 83 | Issue: S 01 | Pages: S1-S270

10.1055/s-0042-1743713 Get It

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials
McCleary, Nadine J. , Harmsen, William S. , Haakenstad, Ellana , Cleary, James M. , Meyerhardt, Jeffrey A. , Zalcberg, John , Adams, Richard , Grothey, Axel , Sobrero, Alberto , Cutsem, Eric Van , Goldberg, Richard M. , Seymour, Michel , Giantonio, Bruce J. , Rothenberg, Mace L., Koopman, Miriam , Schmoll, Hans‐Joachim , Pitot, Henry C., Hoff, Paulo M. , Souglakos, John , Bokemeyer, Carsten , Heinemann, Volker , Chibaudel, Benoist , deGramont, Aimery, Shi, Qian , Sobrero, Alberto F , Van Cutsem, Eric , Peeters, Marc , Tabernero, Josep , Seymour, Matthew T , Saltz, Leonard , Koopman, Miriam , Tebbutt, Niall C , Bokemeyer, Carsten , Heinemann, Volker , Yoshino, Takayuki , De Gramont, Aimery , Shi, Qian , Lichtman, Stuart M , Meyerhardt, Jeffrey A , Zalcberg, John , Adams, Richard , Schmoll, Hans-Joachim , Chibaudel, Benoist , Peeters, Marc , Tabernero, Josep , Saltz, Leonard B. , Arnold, Dirk , Tebbutt, Niall C. , Masi, Gianluca , Yoshino, Takayuki , Gramont, Aimery de , Lichtman, Stuart M.

Mayo Clinic

JNCI Cancer Spectrum | February 25, 2022 | Volume: 6 | Issue: 2 | Pages: No page available

10.1093/jncics/pkac014 | PMID 35603849 Get It

Abstract Background We evaluated the time to progression (TTP) and survival outcomes of second-line therapy for metastatic colorectal cancer among adults aged 70 years and older compared with younger adults following progression on first-line clinical trials. Methods Associations between clinical and disease characteristics, time to initial progression, and rate of receipt of second-line therapy were evaluated. TTP and overall survival (OS) were compared between older and younger adults in first- and second-line trials by Cox regression, adjusting for age, sex, Eastern Cooperative Oncology Group Performance Status, number of metastatic sites and presence of metastasis in the lung, liver, or peritoneum. All statistical tests were 2-sided. Results Older adults comprised 16.4% of patients on first-line trials (870 total older adults aged >70 years; 4419 total younger adults aged ≤70 years, on first-line trials). Older adults and those with Eastern Cooperative Oncology Group Performance Status >0 were less likely to receive second-line therapy than younger adults. Odds of receiving second-line therapy decreased by 11% for each additional decade of life in multivariable analysis (odds ratio = 1.11, 95% confidence interval = 1.02 to 1.21, P = .01). Older and younger adults enrolled in second-line trials experienced similar median TTP and median OS (median TTP = 5.1 vs 5.2 months, respectively; median OS = 11.6 vs 12.4 months, respectively). Conclusions Older adults were less likely to receive second-line therapy for metastatic colorectal cancer, though we did not observe a statistical difference in survival outcomes vs younger adults following second-line therapy. Further study should examine factors affecting decisions to treat older adults with second-line therapy. Inclusion of geriatric assessment may provide better criteria regarding the risks and benefits of second-line therapy.
Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials
Fonseca, Adriana , Faure‐Conter, Cécile , Murray, Matthew J. , Fangusaro, Jason , Bailey, Shivani , Goldman, Stewart , Khatua, Soumen , Frappaz, Didier , Calaminus, Gabriele , Dhall, Girish , Nicholson, James C. , Bouffet, Eric , Bartels, Ute , Dhall, Girish , Bouffet, Éric , Bartels, Ute

Mayo Clinic

Neuro-Oncology | February 24, 2022 | Volume: 24 | Issue: 11 | Pages: 1950-1961

10.1093/neuonc/noac057 | PMID 35218656 Get It

Abstract Background Central Nervous System Non-Germinomatous Germ Cell Tumors (CNS-NGGCT) are rare but curable tumors. Due to their rarity, patients with treatment failures remain a poorly characterized group with unfavorable outcomes. In this study, we sought to characterize patients with treatment failures in a large, prospectively treated cohort. Methods European and North American clinical trials for patients with CNS-NGGCT (SIOP-GCT-96, SFOP-TGM-TC 90/92, COG-ACNS0122, and COG-ACNS1123) were pooled for analysis. Additionally, patients included and treated in the UK and France national registries under strict protocol guidelines were included as an independent, non-overlapping cohort. Results A total of 118 patients experienced a treatment failure. Twenty-four patients had progressive disease during therapy, and additional 11 patients were diagnosed with growing teratoma syndrome (GTS). Patients with GTS are significantly younger and present with local failures and negative tumor markers. Eighty-three individuals experienced disease relapses after treatment ended. Patients’ metastatic relapses presented significantly earlier than local relapses and were associated with tumor marker elevation (OR: 4.39; P = .026). In our analysis, focal or whole-ventricular radiation therapy was not associated with an increased risk of metastatic relapses. Conclusions Herein, we present the largest pooled dataset of prospectively treated patients with relapsed CNS-NGGCT. Our study identified younger age and negative tumor markers to be characteristic of GTS. Additionally, we elucidated that metastatic relapses occur earlier than local relapses are associated with elevated tumor markers and are not associated with the field of radiation therapy. These findings are of utmost importance for the planning of future clinical trials and the implementation of surveillance strategies in these patients.
Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial
Matteson, Eric L. , Distler, Jörg H. W. , Seibold, James R. , Mittoo, Shikha, Dellaripa, Paul F. , Aringer, Martin , Pope, Janet , Distler, Oliver , James, Alexandra, Schlenker‐Herceg, Rozsa, Stowasser, Susanne , Quaresma, Manuel , Flaherty, Kevin R. , Investigators, the INBUILD Trial, Distler, Jörg H W , Aringer, Martin , Pope, Janet , Distler, Oliver , Kelly, Clive Anthony , Hoffmann‐Vold, Anna‐Maria , James, Alexandra, Investigators, the INBUILD Trial

Mayo Clinic

Arthritis & Rheumatology | February 24, 2022 | Volume: 74 | Issue: 6 | Pages: 1039-1047

10.1002/art.42075 | PMID 35199968 Get It

ObjectiveTo analyze the efficacy and safety of nintedanib in patients with fibrosing autoimmune disease–related interstitial lung diseases (ILDs) with a progressive phenotype.MethodsThe INBUILD trial enrolled patients with a fibrosing ILD other than idiopathic pulmonary fibrosis, with diffuse fibrosing lung disease of >10% extent on high‐resolution computed tomography, forced vital capacity percent predicted (FVC%) ≥45%, and diffusing capacity of the lungs for carbon monoxide percent predicted ≥30% to <80%. Patients fulfilled protocol‐defined criteria for progression of ILD within the 24 months before screening, despite management deemed appropriate in clinical practice. Subjects were randomized to receive nintedanib or placebo. We assessed the rate of decline in FVC (ml/year) and adverse events (AEs) over 52 weeks in the subgroup with autoimmune disease–related ILDs.ResultsAmong 170 patients with autoimmune disease–related ILDs, the rate of decline in FVC over 52 weeks was −75.9 ml/year with nintedanib versus −178.6 ml/year with placebo (difference 102.7 ml/year [95% confidence interval 23.2, 182.2]; nominal P = 0.012). No heterogeneity was detected in the effect of nintedanib versus placebo across subgroups based on ILD diagnosis (P = 0.91). The most frequent AE was diarrhea, reported in 63.4% and 27.3% of subjects in the nintedanib and placebo groups, respectively. AEs led to permanent discontinuation of trial drug in 17.1% and 10.2% of subjects in the nintedanib and placebo groups, respectively.ConclusionIn the INBUILD trial, nintedanib slowed the rate of decline in FVC in patients with progressive fibrosing autoimmune disease–related ILDs, with AEs that were manageable for most patients.
Recommendations for effective documentation in regional anesthesia: an expert panel Delphi consensus project
Lotfy, Ahmed , Atterton, B, Crowe, G, Barratta, Jaime L, Johnson, Mark , Viscusi, Eugene R. , Adhikary, Sanjib Das , Albrecht, Éric , Boretsky, Karen , Boublik, Jan , Breslin, Dara S., Ch’ng, Alan Swee Hock , Chuan, Alwin , Conroy, Patrick , Daniel, Craig O. , Daszkiewicz, Andrzej , Delbos, Alain, Dîrzu, Dan Sebastian , Dmytrіiev, Dmytro , Fennessy, Paul , Frizelle, Henry P., Gadsden, Jeff, Gautier, Philippe , Hardman, H. David , Harrop‐Griffiths, W., Hebbard, Peter , Hernandez, Nadia , Hlásny, Jakub , Iohom, Gabriella , Kalagara, Hari , Kinirons, B., Leng, Jody C. , Lim, Yean Chin , Lobo, Clara , Ludwin, Danielle, Macfarlane, Alan , Machi, Anthony , Mahon, Padraig, Mannion, Stephen , McLeod, David H., Merjavy, Peter , Miščuks, Aleksejs , Mitchell, Christopher H. , Μoka, Εleni , Moran, Peter, Ngui, Ann, Nin, Olga C. , OʼDonnell, Brian D. , Pawa, Amit , Perlas, Anahi , Pozek, John-Paul J., Rebelo, Humberto C, Roqués, V, Schroeder, Kristopher M. , Schwartz, Gary , Shorten, George , Stevens, Markus F. , Turbitt, Lloyd , Valdés-Vilches, Luis Fernando , Webster, Katrina, Wolmarans, Morné , Woodworth, Glenn E. , Worek, Andrew K, Moran, EML , Ahmed, Hassan M , Viscusi, Eugene , Adhikary, Sanjib , Byrne, Kelly , Chuan, Alwin , Dirzu, Dan Sebastian , Dmytriiev, Dmytro , Gupta, Rajnish K , Ip, Vivian H Y , Jeng, Christina L , Johnson, Rebecca L , Lim, Yean Chin , Macfarlane, Alan James Robert , Machi, Anthony T , Merjavy, Peter , Pawa, Amit , Perlas, Anahi , Porter, Steven B , Schwenk, Eric S , Sermeus, Luc , Srinivasan, Karthikeyan , Theodoraki, Kassiani , Volk, Thomas , Wilson, Sylvia H , Woodworth, Glenn , Moran, E M Louise , Kalagara, Hari , Lobo, Clara , Moka, Eleni , Albrecht, Eric , Crowe, Gillian-Genevieve , Ch'ng, Alan, Fischer, H. B. J. , Gupta, Rajnish K. , Gürkan, Yavuz , Ip, Vivian , Johnson, Rebecca L. , Lansdown, Andrew Kenneth, Porter, Steven B. , Schwenk, Eric S. , Volk, Thomas , Webster, Katrina, Wiesmann, Thomas

Mayo Clinic

Regional Anesthesia & Pain Medicine | February 22, 2022 | Volume: 47 | Issue: 5 | Pages: 301-308

10.1136/rapm-2021-103136 | PMID 35193970 Get It

Background and objectives Documentation is important for quality improvement, education, and research. There is currently a lack of recommendations regarding key aspects of documentation in regional anesthesia. The aim of this study was to establish recommendations for documentation in regional anesthesia. Methods Following the formation of the executive committee and a directed literature review, a long list of potential documentation components was created. A modified Delphi process was then employed to achieve consensus amongst a group of international experts in regional anesthesia. This consisted of 2 rounds of anonymous electronic voting and a final virtual round table discussion with live polling on items not yet excluded or accepted from previous rounds. Progression or exclusion of potential components through the rounds was based on the achievement of strong consensus. Strong consensus was defined as ≥75% agreement and weak consensus as 50%–74% agreement. Results Seventy-seven collaborators participated in both rounds 1 and 2, while 50 collaborators took part in round 3. In total, experts voted on 83 items and achieved a strong consensus on 51 items, weak consensus on 3 and rejected 29. Conclusion By means of a modified Delphi process, we have established expert consensus on documentation in regional anesthesia.